Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Expenditures | 2 | 2016 | 211 | 0.960 |
Why?
|
| Health Plan Implementation | 3 | 2019 | 90 | 0.840 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 88 | 0.660 |
Why?
|
| Cancer Care Facilities | 2 | 2019 | 884 | 0.580 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 1382 | 0.550 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 1225 | 0.520 |
Why?
|
| Symptom Assessment | 1 | 2017 | 267 | 0.510 |
Why?
|
| Neoplasms | 7 | 2019 | 15193 | 0.460 |
Why?
|
| Medical Oncology | 3 | 2020 | 1423 | 0.440 |
Why?
|
| Quality Improvement | 1 | 2019 | 851 | 0.410 |
Why?
|
| Stress, Psychological | 1 | 2017 | 1000 | 0.360 |
Why?
|
| Vulnerable Populations | 3 | 2020 | 167 | 0.310 |
Why?
|
| Aromatase Inhibitors | 1 | 2005 | 305 | 0.220 |
Why?
|
| Hospitals, Community | 2 | 2019 | 79 | 0.200 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 14289 | 0.190 |
Why?
|
| Betapapillomavirus | 2 | 2017 | 5 | 0.190 |
Why?
|
| Hospitals, Public | 2 | 2019 | 64 | 0.180 |
Why?
|
| Prescription Drug Misuse | 1 | 2019 | 11 | 0.180 |
Why?
|
| Hematology | 1 | 2020 | 104 | 0.170 |
Why?
|
| Education, Distance | 1 | 2020 | 93 | 0.170 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 56 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 98 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2016 | 860 | 0.160 |
Why?
|
| Nursing Staff, Hospital | 1 | 2019 | 69 | 0.160 |
Why?
|
| Papillomavirus Infections | 2 | 2017 | 980 | 0.160 |
Why?
|
| Workflow | 1 | 2019 | 275 | 0.160 |
Why?
|
| Breast Neoplasms | 5 | 2020 | 15694 | 0.150 |
Why?
|
| Genetic Counseling | 2 | 2018 | 380 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 289 | 0.140 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 390 | 0.140 |
Why?
|
| Policy Making | 1 | 2016 | 85 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2016 | 231 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 259 | 0.130 |
Why?
|
| Affective Symptoms | 1 | 2015 | 102 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 671 | 0.120 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 374 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2017 | 195 | 0.120 |
Why?
|
| Cancer Pain | 1 | 2019 | 312 | 0.120 |
Why?
|
| Research | 1 | 2016 | 415 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 292 | 0.110 |
Why?
|
| Pain Management | 2 | 2019 | 668 | 0.110 |
Why?
|
| Genetic Testing | 2 | 2018 | 1589 | 0.110 |
Why?
|
| Mass Screening | 2 | 2020 | 1509 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.110 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 735 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2020 | 5687 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 697 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.100 |
Why?
|
| Pain Measurement | 1 | 2015 | 953 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1303 | 0.090 |
Why?
|
| Humans | 18 | 2020 | 261506 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 1371 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2403 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 2265 | 0.080 |
Why?
|
| Time Factors | 2 | 2019 | 12926 | 0.080 |
Why?
|
| Rectal Neoplasms | 1 | 2016 | 1202 | 0.080 |
Why?
|
| Pain | 1 | 2015 | 1658 | 0.070 |
Why?
|
| Palliative Care | 1 | 2017 | 2037 | 0.070 |
Why?
|
| Receptors, Progesterone | 2 | 2013 | 1392 | 0.060 |
Why?
|
| United States | 3 | 2017 | 15433 | 0.060 |
Why?
|
| Poverty | 2 | 2018 | 471 | 0.060 |
Why?
|
| Postmenopause | 1 | 2005 | 378 | 0.060 |
Why?
|
| Receptors, Estrogen | 2 | 2013 | 2086 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5539 | 0.050 |
Why?
|
| Texas | 3 | 2020 | 6311 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5437 | 0.050 |
Why?
|
| Female | 10 | 2020 | 141928 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4654 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 13658 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 4638 | 0.040 |
Why?
|
| Hospitals, County | 1 | 2018 | 28 | 0.040 |
Why?
|
| Middle Aged | 7 | 2020 | 86204 | 0.040 |
Why?
|
| Documentation | 1 | 2019 | 207 | 0.040 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2018 | 153 | 0.040 |
Why?
|
| Integrative Medicine | 1 | 2017 | 39 | 0.040 |
Why?
|
| Learning | 1 | 2020 | 403 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 3890 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2016 | 75 | 0.040 |
Why?
|
| Adult | 6 | 2020 | 77950 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2017 | 126 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2015 | 76 | 0.030 |
Why?
|
| Aged | 5 | 2020 | 70117 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 151 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2020 | 37905 | 0.030 |
Why?
|
| Mammography | 1 | 2020 | 1010 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 918 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 649 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 11538 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2015 | 309 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2015 | 387 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 627 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 573 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 1258 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 348 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2005 | 4975 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2018 | 821 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 674 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 756 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 1209 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2016 | 621 | 0.020 |
Why?
|
| Vaccination | 1 | 2017 | 1123 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 1052 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2013 | 291 | 0.020 |
Why?
|
| Telemedicine | 1 | 2015 | 471 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2803 | 0.020 |
Why?
|
| Young Adult | 2 | 2018 | 21445 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 2316 | 0.020 |
Why?
|
| Male | 4 | 2020 | 123000 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 6100 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 1833 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 9244 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 29902 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 4314 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4549 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 14889 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 5377 | 0.010 |
Why?
|
| Quality of Life | 1 | 2015 | 4532 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 17523 | 0.010 |
Why?
|